Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Chardan Genetic Medicines Conference (Virtual) Transcript

Oct 05, 2020 / 12:00PM GMT
Release Date Price: $9.64
Keay Thomas Nakae;Alexander D. Macrae
Chardan Capital Markets, LLC, Research Division - Senior Research Analyst of Therapeutics, Devices and Diagnostics;Sangamo

Good morning. Thank you, everyone, for attending our Fourth Annual Genetic Medicines Conference, which has gone to a virtual format this year. My name is Keay Nakae, one of the senior health care analysts at Chardan, where our vision is to help identify companies with high potential for investment returns based on creating real value for society through disruptive innovation.

Our compliance department has asked us to read this message, and this is effective for the whole conference. Ideas and recommendations presented are solely those of the presenter and not Chardan. Presenters have been advised not to discuss any confidential or material nonpublic information. Additionally, any KOLs speaking may have investments or other interests in the names they discuss.

With that, it's my pleasure to introduce our first guest from Sangamo Therapeutics, Chief Executive Officer, Dr. Sandy Macrae. Welcome.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot